Long‐term ultra‐low‐dose acyclovir against varicella‐zoster virus reactivation after allogeneic hematopoietic stem cell transplantation

Abstract excerpt

To evaluate the efficacy of long-term prophylaxis with ultra-low-dose acyclovir against varicella-zoster virus (VZV) reactivation, we analyzed the records of 242 Japanese adult patients who underwent allogeneic hematopoietic stem cell transplantation for the first time from 1995 to 2006 at our hospital. We started long-term oral acyclovir at 200 mg/day in July 2001. Acyclovir was continued until the end of...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cytomegalovirus and herpesvirus research
• Share to Hematopoietic Stem Cell Transplantation
• Share to Herpesvirus Infections and Treatments